What is Niagen Bioscience, Inc. Common Stock's market cap?

Niagen Bioscience, Inc. Common Stock (NAGE) has a market capitalization of $273.2M and trades on NASDAQ.

What is Niagen Bioscience, Inc. Common Stock's revenue and profitability?

Niagen Bioscience, Inc. Common Stock generated $130.4M in trailing twelve-month revenue with net income of $18.6M, representing a net margin of 14.3%. Gross margin stands at 64.3%. These figures are based on the Q1 2026 filing.

Who are Niagen Bioscience, Inc. Common Stock's competitors?

Niagen Bioscience, Inc. Common Stock's key competitors include eXoZymes Inc. Common Stock, Nature's Sunshine Products Inc., Lifevantage Corporation Common Stock (Delaware), and others. These companies compete in similar markets and product categories.

Who does Niagen Bioscience, Inc. Common Stock partner with?

Niagen Bioscience, Inc. Common Stock's notable partners include A.S. Watson Group, Amazon, iHerb, and others.

What subsidiaries does Niagen Bioscience, Inc. Common Stock have?

Niagen Bioscience, Inc. Common Stock's subsidiaries include ChromaDex, Inc..

Where is Niagen Bioscience, Inc. Common Stock headquartered?

Niagen Bioscience, Inc. Common Stock is headquartered in United States of America. It has been publicly traded since 2008.

Niagen Bioscience, Inc. Common Stock

NAGE

Niagen Bioscience is a global bioscience company focused on healthy aging through the research and commercialization of nicotinamide adenine dinucleotide (NAD+) precursors.

Market cap

$273.18M-74.9%

Revenue$130.4M+20.8%

Net income$18.6M+32.1%

EPS (diluted)$0.21+23.5%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 6, 2026

Revenue$31.5MBeat by $444.0K EPS$0.07Beat by $0.01

Read the full report

Next report

Aug 5, 2026 (in a month)

Revenue estimate$31.7M

EPS estimate$0.01

Financials

Q1 2026

Income statement

See full

Revenue$31.5M+3.3%

Gross profit$20.0M+3.3%

Operating income$1.6M-67.0%

Net income$6.3M+24.8%

EPS (diluted)$0.07+16.7%

Balance sheet

See full

Cash & equivalents$66.5M+19.7%

Total debt$2.6M-26.9%

Total equity$82.3M+48.8%

Total assets$114.3M+40.6%

Cash flow

See full

Operating cash flow-$1.2M-115%

Valuation & ratios

Valuation

See full

Market cap$254.07M-74.9%

Enterprise value$190.09M-79.7%

P/E13.6×-43.5×

P/S2×-6.8×

Profitability

See full

Gross margin64.3%+1.8pp

Operating margin10%-2.2pp

Net margin14.3%+1.2pp

Returns & leverage

See full

Return on equity27.1%-6.4pp

Debt / equity0×0.0×

Current ratio4.6×+0.9×

Segments

By segment

See full

Consumer Products segment$22.4M+4.2%

Ingredients segment$8.6M+4.8%

Analytical Reference Standards and Services segment$423.0K-47.8%

Corporate and other$74.0K—

Competitors

By market cap

Abbott$158.05B-33.9%

Nature's Sunshine Products$383.4M+39.9%

NAG

Niagen Bioscience, Inc. Common Stock$254.1M-76.7%

Lifevantage Corporation$78.7M-51.3%

eXoZymes Inc. Common Stock$76.8M-5.6%

Biote Corp.$57.3M-57.5%

Natural Health Trends$15.2M-69.5%

Jupiter Neurosciences, Inc.$10.3M-74.0%

By revenue growth

NAG

Niagen Bioscience, Inc. Common Stock+20.8%

Nature's Sunshine Products+7.3%

Abbott+6.6%

Biote Corp.-5.6%

Lifevantage Corporation-12.2%

By net margin

NAG

Niagen Bioscience, Inc. Common Stock14.29%+1.2pp

Abbott13.91%—

Biote Corp.8.29%-2.3pp

Nature's Sunshine Products4.06%—

Lifevantage Corporation2.94%-1.2pp

eXoZymes Inc. Common Stock-2,909.12%—

Profile

Niagen Bioscience is a global bioscience company focused on healthy aging through the research and commercialization of nicotinamide adenine dinucleotide (NAD+) precursors. The company leverages a proprietary form of nicotinamide riboside (Niagen) to develop cellular health products that address the natural decline of NAD+ levels in the human body. Its value proposition is built on a robust portfolio of owned and licensed patents and extensive clinical research collaborations with leading global academic institutions.

Competitive position

Niagen Bioscience is a world leader in the NAD+ space, distinguished by its extensive patent portfolio and the ChromaDex External Research Program (CERP).

GeographiesUnited States, Canada, Hong Kong, Macau, European Union, Australia

Customer segmentsRetail consumers, Pharmaceutical manufacturers, Healthcare providers

Business modelB2C e-commerce, B2B ingredient supply, Research and Development, Licensing

SuppliersRaw material chemical suppliers, Contract manufacturers, Academic research institutions, Patent licensors

CustomersIndividual consumers, Amazon, A.S. Watson Group, iHerb, 503B compounding facilities

CountryUnited States of America

Listed2008

CEORobert N. Fried

FilingsSEC EDGAR

Ask your AI about Niagen Bioscience, Inc. Common Stock.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Niagen Bioscience, Inc. Common Stock's market cap?: Niagen Bioscience, Inc. Common Stock (NAGE) has a market capitalization of $273.2M and trades on NASDAQ.
What is Niagen Bioscience, Inc. Common Stock's revenue and profitability?: Niagen Bioscience, Inc. Common Stock generated $130.4M in trailing twelve-month revenue with net income of $18.6M, representing a net margin of 14.3%. Gross margin stands at 64.3%. These figures are based on the Q1 2026 filing.
Who are Niagen Bioscience, Inc. Common Stock's competitors?: Niagen Bioscience, Inc. Common Stock's key competitors include eXoZymes Inc. Common Stock, Nature's Sunshine Products Inc., Lifevantage Corporation Common Stock (Delaware), and others. These companies compete in similar markets and product categories.
Who does Niagen Bioscience, Inc. Common Stock partner with?: Niagen Bioscience, Inc. Common Stock's notable partners include A.S. Watson Group, Amazon, iHerb, and others.
What subsidiaries does Niagen Bioscience, Inc. Common Stock have?: Niagen Bioscience, Inc. Common Stock's subsidiaries include ChromaDex, Inc..
Where is Niagen Bioscience, Inc. Common Stock headquartered?: Niagen Bioscience, Inc. Common Stock is headquartered in United States of America. It has been publicly traded since 2008.